FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Market Closed - Börse Stuttgart 19:05:05 24/06/2024 BST | ||
| 111.6 EUR | -0.56% |
|
| Current month | +46.19% | ||
| 1 month | +35.03% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24/06/24 | 111.6 | -0.56% |
| 21/06/24 | 112.2 | +2.12% |
| 20/06/24 | 109.9 | +1.54% |
| 19/06/24 | 108.2 | +2.74% |
| 18/06/24 | 105.3 | -5.85% |
Delayed Quote Börse Stuttgart
Last update June 24, 2024 at 07:05 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MF1GUH |
| ISIN | DE000MF1GUH6 |
| Date issued | 06/02/2017 |
| Strike | 823.6 kr |
| Maturity | Unlimited |
| Parity | 0.2 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 245.4 € |
|---|---|
| Lowest since issue | 2.45 € |
| Spread | 0.36 € |
| Spread % | 0.32% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
988.4
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.48%
- Stock Market
- Certificates
- Certificat
